MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of Psilocybins for overcoming disease. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property.
Stock Performance
MYND Life Sciences Inc. News 6 articles
- MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia
- MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias
- MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist
- MYND Life Sciences Announces DTC Eligibility
- MYND Life Sciences Inc. Establishes Scientific Advisory Board
- MYND Life Sciences Inc. Announces Public Listing on the CSE